ClinicalTrials.gg

Program

TQB3473

A development code. Also written as “TQB3473 Tablets”.

In Sino Biopharmaceutical's pipeline, SYK抑制剂. Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Hematologic Neoplasms, led by Sino Biopharmaceutical.

Furthest: phase 3, since Mar 24, 20253 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical32 open or runningphase 3since Mar 24, 2025May 28, 2020Mar 2027phase 3 · NCT06900920
  • Named in Sino Biopharmaceutical’s own pipeline as TQB3473, phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 28, 2020First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT04412577 · 57 enrolled · China
  2. Mar 24, 2025Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT06900920 · 199 planned · China
  3. Jul 16, 2025Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07083739 · 320 planned · China

Ahead

  1. Mar 2027Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT06900920
  2. Sep 2027Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07083739

TargetBeta

“SYK抑制剂”the company's pipeline, read by Claude · source

Other programs on SYK

ProgramCompanyFurthest phaseStudies
sovleplenibruleHUTCHMEDphase 314

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07083739Purpura, Thrombocytopenic, Idiopathic · China2Not yet recruitingSep 2027320
NCT06900920Purpura, Thrombocytopenic, Idiopathic · China3RecruitingMar 2027199
NCT04412577Hematologic Neoplasms · China1UNKNOWNDec 202157

How it is read

Names in the registry

  • “TQB3473 Tablets”, 2 entries
  • “TQB3473”, 1 entry

Codes read as this program: TQB3473.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.